EPRX

SEC filing EPRX Announces Annual General Meeting on June 18, 2026, to Elect Directors and Appoint Auditor

3d ago

SEC filing EPRX Reports 65% EREFS Reduction, 20-Injection Protocol Shows Fibrosis/Inflammation Improvement, Phase 2b Data Expected Q4 2026

28d ago

SEC filing EPRX Reports 36-Week Tissue Health & Symptom Data from Highest Dose Cohort in RESOLVE Trial, 66% Clinical Remission, 90% Tissue Health Reduction, No SAEs, 230+ Patient-Months Follow-Up

42d ago

SEC filing EPRX Reports 24-Week Symptom Response in RESOLVE Trial, 76% Clinical Remission, 4-Point SDI Reduction, No SAEs, 220+ Patient-Months

77d ago

SEC filing EPRX Announces $150M Offering to Advance EP-104GI for Eosinophilic Esophagitis, Phase 2/3 Trials, IP Expansion

103d ago

News Lyft Working on Teen Rides Feature as It Plays Catch-Up With Uber

126d ago

Short interest Short Interest

140d ago

Scanner Unusual volume (z=4.5)

161d ago

Scanner Unusual volume (z=4.5)

163d ago

Scanner Unusual volume (z=4.5)

164d ago

Short interest Short Interest

165d ago